abstract |
The present invention relates to novel crystalline forms of (4- {4- [5- (6-trifluoro-methyl-pyridin-3-i-amino) -pyridin-2-yl] -phenyl} -cyclohexyl) -acetic acid , sodium salt, and its use in the treatment or prevention of a condition or disorder associated with the activity of DGAT1 in animals, in particular in humans. It also refers to processes for the elaboration of these novel crystalline forms. |